DuPont develops second-generation contrast agent
This article was originally published in Clinica
Executive Summary
DuPont has submitted a new drug application (NDA) to the FDA for Definity (perflutren), its second-generation contrast agent for ultrasound imaging. Formerly known as DMP 115, the contrast agent is one of several being developed that are based on small gas-filled bubbles. Others include MBI's Optison and Sonus Pharmaceuticals' Echogen.